Abiopharma

🔍 Li David H (Executive)

Company: HEXCEL CORP /DE/ (HXL)

Report Date: 2026-04-03

Detailed Transactions and Holdings:

• Acquired 457 shares of Common Stock (Direct)
  Date: 2026-04-04 | Code: M | equity_swap_involved: false | shares_owned_after: 1,542.00 | transaction_form_type: 4
• Acquired 277 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-03 | Code: A | equity_swap_involved: false | shares_owned_after: 277.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 457 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-04 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a conditional right to receive one share of common stock of the issuer.
• F2: The shares of common stock underlying the RSUs will be converted into an equivalent number of shares of common stock of the issuer on the first anniversary of the date of grant.